Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Mucpharm Pty Ltd. is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 3 distinct examiners, which introduces a variety of examiner perspectives into the prosecution process. Additionally, the portfolio is active in 3 distinct art units, indicating that the company's pharmaceutical innovations are being reviewed across several different specialized groups at the USPTO. This diversity suggests a broad technical scope for the company's current biotechnology patent applications. Navigating 3 distinct art units requires a versatile approach to addressing different sets of prior art and examination guidelines.
IANNUZO, NATALIE NMN is the busiest examiner for the company, with 1 pending office action currently assigned. Given the total of 3 pending office actions, the busiest examiner pending count of 1 shows that the workload is distributed equally among the 3 distinct examiners. This breadth across 3 distinct art units and multiple examiners may require a more varied prosecution strategy than a more centralized portfolio. No single examiner or art unit holds a majority of the company's active pharmaceutical matters. This distributed workload can provide the company with a more resilient patent strategy, as it is not overly dependent on any single examiner or art unit's decision.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IANNUZO, NATALIE NMN | 1 | 12.5% | +71.4% |
| FAN, LYNN Y | 1 | 47.3% | +49.5% |
| FERNANDEZ, SUSAN EMILY | 1 | 52.5% | +60.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705481 | METHODS FOR TREATING RESPIRATORY DISEASES | IANNUZO, NATALIE NMN | — |
| 17922709 | PREVENTING AND TREATING VIRAL INFECTIONS | FAN, LYNN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705481 | METHODS FOR TREATING RESPIRATORY DISEASES | IANNUZO, NATALIE NMN | — |
| 17922709 | PREVENTING AND TREATING VIRAL INFECTIONS | FAN, LYNN Y | — |
| 16975058 | FORMULATIONS CONTAINING MUCIN-AFFECTING PROTEASES | FERNANDEZ, SUSAN EMILY | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1759 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705481 | METHODS FOR TREATING RESPIRATORY DISEASES | IANNUZO, NATALIE NMN | 1653 | §102§103§112DP | Non-Final OA | — | Pending | Apr 26, 2024 |
| 17922709 | PREVENTING AND TREATING VIRAL INFECTIONS | FAN, LYNN Y | 1759 | §103§112 | Final Rejection | — | Pending | Nov 01, 2022 |
| 16975058 | FORMULATIONS CONTAINING MUCIN-AFFECTING PROTEASES | FERNANDEZ, SUSAN EMILY | 1651 | §112 | Non-Final OA | — | Pending | Aug 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial